These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 29856033)

  • 21. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
    Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
    Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Huntingtin-lowering strategies for Huntington's disease.
    Barker RA; Fujimaki M; Rogers P; Rubinsztein DC
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1125-1132. PubMed ID: 32745442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pathogenic proteolysis-resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function.
    Kim H; Lenoir S; Helfricht A; Jung T; Karneva ZK; Lee Y; Beumer W; van der Horst GB; Anthonijsz H; Buil LC; van der Ham F; Platenburg GJ; Purhonen P; Hebert H; Humbert S; Saudou F; Klein P; Song JJ
    JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35943803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
    Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
    Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
    J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
    Tabrizi SJ; Ghosh R; Leavitt BR
    Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer: From Wild-Type to Mutant Huntingtin.
    Thion MS; Humbert S
    J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Strategies for mutant gene expression silencing in Huntington’s disease therapy].
    Fiszer A; Nowak B
    Postepy Biochem; 2020 Mar; 66(1):1-9. PubMed ID: 33320475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
    Leavitt BR; Kordasiewicz HB; Schobel SA
    JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease.
    Howland DS; Munoz-Sanjuan I
    Mov Disord; 2014 Sep; 29(11):1397-403. PubMed ID: 25155258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gene silencing approaches for the treatment of Huntington's disease].
    Merienne N; Déglon N
    Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How the gene behind Huntington's disease could be neutralized.
    Drew L
    Nature; 2018 May; 557(7707):S39-S41. PubMed ID: 29844556
    [No Abstract]   [Full Text] [Related]  

  • 38. mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs
    Allen S; O'Reilly D; Miller R; Sapp E; Summers A; Paquette J; Echeverria Moreno D; Bramato B; McHugh N; Yamada K; Aronin N; DiFiglia M; Khvorova A
    Nucleic Acid Ther; 2024 Aug; 34(4):164-172. PubMed ID: 39023561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research.
    Aron Badin R
    Methods Mol Biol; 2018; 1780():267-284. PubMed ID: 29856024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gene-selective treatment approaches for Huntington's disease].
    Mühlbäck A; Lindenberg KS; Saft C; Priller J; Landwehrmeyer GB
    Nervenarzt; 2020 Apr; 91(4):303-311. PubMed ID: 32179957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.